1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (650) 595-0180
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer†
Article first published online: 21 JUL 2008
DOI: 10.1002/cncr.23669
Copyright © 2008 American Cancer Society
Additional Information
How to Cite
Higano, C. S., Corman, J. M., Smith, D. C., Centeno, A. S., Steidle, C. P., Gittleman, M., Simons, J. W., Sacks, N., Aimi, J. and Small, E. J. (2008), Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer, 113: 975–984. doi: 10.1002/cncr.23669
- †
All patients provided informed consent.
Publication History
- Issue published online: 20 AUG 2008
- Article first published online: 21 JUL 2008
- Manuscript Accepted: 11 APR 2008
- Manuscript Revised: 9 APR 2008
- Manuscript Received: 14 DEC 2007
Funded by
- Cell Genesys, South San Francisco, California, to each investigator
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , , , , , , , , , Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, The Lancet Oncology, 2012, 13, 5, 509
- You have free access to this content2, , , , , , Immunotherapy of cancer in 2012, CA: A Cancer Journal for Clinicians, 2012, 62, 3Direct Link:
- 3, , , , , , , , , Novel therapeutics for the management of castration-resistant prostate cancer (CRPC), BJU International, 2012, 109, 7Direct Link:
- 4, , Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy, Cancer Immunology, Immunotherapy, 2012, 61, 4, 453
- 5, Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: A review, Cancer Treatment Reviews, 2012,
- 6
- 7, , , , Cancer Immunotherapy: Sipuleucel-T and Beyond, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011, 31, 8Direct Link:
- 8, , Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy, Journal of Clinical Immunology, 2011, 32, 1, 25
- 9, , Current Treatment Strategies for Castration-Resistant Prostate Cancer, Korean Journal of Urology, 2011, 52, 3, 157
- 10, , , , From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer, Expert Review of Vaccines, 2011, 10, 6, 743
- 11, , , Immunotherapy for the treatment of prostate cancer, Nature Reviews Clinical Oncology, 2011, 8, 9, 551
- 12, , , Immunotherapy in prostate cancer: Emerging strategies against a formidable foe, Vaccine, 2011, 29, 38, 6485
- 13, , , , , , , , , , , , , , Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer, Cancer Immunology, Immunotherapy, 2011, 60, 5, 715
- 14
- 15, , , , , , , , , , , New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety, European Urology, 2011, 60, 2, 279
- 16, , , Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature, Cancer Treatment Reviews, 2011, 37, 6, 444
- 17
- 18, , , , Recent advances in immunotherapy for the treatment of prostate cancer, Expert Opinion on Biological Therapy, 2011, 11, 8, 997
- You have free access to this content19, , Recent developments in prostate cancer biomarker research: therapeutic implications, British Journal of Clinical Pharmacology, 2011, 71, 2Direct Link:
- 20, , , T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics, Trends in Molecular Medicine, 2011, 17, 1, 47
- 21, , Zweitlinientherapie beim kastrationsresistenten Prostatakarzinom (CRPC), Der Urologe, 2011, 51, 3, 357
- 22, , , , , , Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy, Cancer Immunology, Immunotherapy, 2010, 59, 9, 1313
- 23, , , Castration-refractory prostate cancer: New drugs in the pipeline, Advances in Therapy, 2010, 27, 5, 285
- 24
- 25, , Current status of immunological therapies for prostate cancer, Current Opinion in Urology, 2010, 20, 3, 241
- 26, , Directing dendritic cell immunotherapy towards successful cancer treatment, Immunotherapy, 2010, 2, 1, 37
- 27, , , , Horizon scanning for novel therapeutics for the treatment of prostate cancer, Annals of Oncology, 2010, 21, Supplement 7, vii43
- 28, , , , , , , Human leukemic cells loaded with α-galactosylceramide (α-GalCer) activate murine NKT cells in situ, International Journal of Hematology, 2010, 92, 1, 152
- You have free access to this content29, , , , , , , , , Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer, Cancer Science, 2010, 101, 3Direct Link:
- 30, Immunotherapy for Prostate Cancer: An Emerging Treatment Modality, Urologic Clinics of North America, 2010, 37, 1, 121
- 31, , , Novel targeted therapeutics for metastatic castration-resistant prostate cancer, Cancer Letters, 2010, 291, 1, 1
- 32, Prostate cancer as a model for tumour immunotherapy, Nature Reviews Immunology, 2010, 10, 8, 580
- 33, , , , , Strategies for Cancer Vaccine Development, Journal of Biomedicine and Biotechnology, 2010, 2010, 1
- 34, , , Targeted therapeutic approaches for hormone-refractory prostate cancer, Cancer Treatment Reviews, 2010, 36, 2, 122
- 35, , The role of docetaxel based therapy for prostate cancer in the era of targeted medicine, International Journal of Urology, 2010, 17, 3Direct Link:
- 36, , , , Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art, Seminars in Immunology, 2010, 22, 3, 105
- 37, , Update: Immunological Strategies for Prostate Cancer, Current Urology Reports, 2010, 11, 3, 202
- 38, , , , , , Validation of a quantitative flow cytometer assay for monitoring HER-2/neu expression level in cell-based cancer immunotherapy products, Biologicals, 2010, 38, 2, 249
- 39, , , , , , , , Validation of cell density and viability assays using Cedex automated cell counter, Biologicals, 2010, 38, 3, 393
- 40, What's New in Hormone-refractory Prostate Cancer Treatment, Journal of the Korean Medical Association, 2010, 53, 2, 126
- 41, , , , , , , , Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies, Clinical Immunology, 2009, 133, 2, 184
- 42, , , , , , , , Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets, European Urology, 2009, 56, 4, 594
- 43, , , , , , Dendritic cell-based cancer immunotherapies, Archivum Immunologiae et Therapiae Experimentalis, 2009, 57, 3, 189
- 44, , Emerging therapies in castrate-resistant prostate cancer, Current Opinion in Oncology, 2009, 21, 3, 260
- 45, , , , Immunmodulatorische Therapieansätze beim Prostatakarzinom, Der Urologe, 2009, 48, 7, 755
- 46
- 47, , , , , , , , , , , Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer, The Prostate, 2009, 69, 9Direct Link:
- 48, , , , , , , , , , , , , , , Therapeutic Vaccination with an Interleukin-2–Interferon-γ-Secreting Allogeneic Tumor Vaccine in Patients with Progressive Castration-Resistant Prostate Cancer: A Phase I/II Trial, Human Gene Therapy, 2009, 20, 12, 1641